Gefjonpharma
Gefjon Pharma utilizes a proprietary hyper-vesiculating outer membrane vesicle (OMV) platform technology for high-yield, cost-effective production of bio-industrials and therapeutics. The company's initial focus is developing a broad-spectrum E. coli vaccine for poultry, leveraging an aerosol application method. This vaccine aims to reduce antimicrobial consumption, improve animal welfare, and enhance producer profitability.
Traction –/10
HQ unknown
Updated 5 months ago
Funding
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Gefjon Pharma utilizes a proprietary hyper-vesiculating outer membrane vesicle (OMV) platform technology for high-yield, cost-effective production of bio-industrials and therapeutics. The company's initial focus is developing a broad-spectrum E. coli vaccine for poultry, leveraging an aerosol application method. This vaccine aims to reduce antimicrobial consumption, improve animal welfare, and enhance producer profitability.